Differential impairment of triazolam and zolpidem clearance by ritonavir.


BACKGROUND The viral protease inhibitor ritonavir has the capacity to inhibit and induce the activity of cytochrome P450-3A (CYP3A) isoforms, leading to drug interactions that may influence the efficacy and toxicity of other antiretroviral therapies, as well as pharmacologic treatments of coincident or complicating diseases. METHODS The inhibitory effect… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.